Therapeutic Response

BRCA1 pathogenic variants status confers therapeutic sensitivity to Abiraterone acetate in combination with Niraparib and Prednisone in patients with Prostate Adenocarcinoma.

Statements

Source and description

Akeega (abiraterone acetate and niraparib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.